Products are for research use only, not for human use

Metal complex · identity partially verified

AHK-Cu

AHK-Cu is the copper(II) complex of the tripeptide L-alanyl-L-histidyl-L-lysine (Ala-His-Lys). It is a synthetic analogue of the plasma copper-binding peptide GHK in which alanine replaces the N-terminal glycine.

Updated · 25 sources read · How this library is built

  1. A1
  2. H2
  3. K3
One-letter code, H-Ala-His-Lys-OH (free N-terminal amine, free C-terminal carboxylate), all residues L, with one Cu(II) ion bound in the registered 1:1 form. Outlined positions carry a modification listed below.

AHK-Cu in brief

AHK-Cu is the copper(II) complex of the synthetic tripeptide L-alanyl-L-histidyl-L-lysine, the plasma peptide GHK with alanine in place of its N-terminal glycine; the cosmetic ingredient sector numbers the pair, GHK-Cu as Copper Tripeptide-1 and this complex as Copper Tripeptide-3. The free peptide is a registered substance (CAS 126828-32-8); the complex appears only as a depositor record and as a supplier catalogue entry, and its identity here is partially verified. One primary study has tested it, in human scalp follicle organ culture and cultured dermal papilla cells, read only as an abstract, through a 2026 review and through a supplier's summary of the full text, with no independent replication. That study's effect was concentration-dependent in both directions: follicle elongation increased at the lowest concentrations tested and, on the supplier's reading of the same figures, fell at the highest. Its copper chemistry is entirely inferred from the well-studied Xxx-His class, since no stability constant, spectroscopic assignment or structure for Cu(II)-AHK has been published. Neither the complex nor the free peptide is authorised as a medicine in any database searched, and neither is named on the World Anti-Doping Agency 2026 Prohibited List.[1,2,3,4,5,6,7]

AHK-Cu regulatory status

Neither the copper complex nor the copper-free peptide is authorised as a medicine anywhere checked: Drugs@FDA, the European Medicines Agency medicines database and the Health Canada Drug Product Database hold no record of AHK-Cu or of Ala-His-Lys (all searched November 2026). Neither appears on the FDA's list of bulk drug substances nominated for compounding that may present significant safety risks, so no agency concern about them is on that record, and neither is named anywhere on the World Anti-Doping Agency 2026 Prohibited List, by name or by class. The material has two other sector positions and both are stated plainly here: it is catalogued and labelled in the cosmetic ingredient sector as Copper Tripeptide-3, the numbered counterpart of Copper Tripeptide-1 for GHK-Cu, and it is catalogued as a laboratory research chemical carrying the supplier's own statement that it is not for human or veterinary use. The sector name was read from chemical suppliers' product records and from PubChem's depositor synonyms; a November 2026 search of the European Commission CosIng inventory returned Copper Tripeptide-1 and Copper Tripeptide-34 HCl but no entry under Copper Tripeptide-3, so it is reported here as a sector and trade name rather than as an EU-inventoried ingredient name. No retraction, correction or expression of concern was found for any work cited on this page.[8,9,10,11,7,3,12,5]

AHK-Cu at a glance

  • AHK-Cu is Ala-His-Lys with bound copper(II): the tripeptide GHK with its first residue changed from glycine to alanine. The free peptide is a registered substance (CAS 126828-32-8); the copper complex appears only as a depositor record in PubChem and as a supplier catalogue entry, where it is titled with its cosmetic-sector name, Copper Tripeptide-3.[6,13,5,3]
  • The complex was claimed as a new compound in a ProCyte patent granted in 1996, which reports no measurements on it.[14]
  • One primary study has tested AHK-Cu: in human scalp follicles in organ culture and in cultured dermal papilla cells, it changed follicle elongation, cell proliferation and apoptosis-related protein levels, and the direction of the elongation change depended on the concentration used.[1,2,3]
  • Of the five studies summarised on this page, one tested AHK-Cu itself. The other four tested Cu(II) bound to Ala-His-His, copper complexes of GHK and two of its analogues, a copper-free vitamin C conjugate of AHK, and synthetic dimeric peptides against copper-free AHK as a comparator, so they are evidence about the class and the ligand rather than measurements on this complex.[15,16,17,18]
  • No measurement of how AHK binds copper has been published. Its copper chemistry is inferred from the well-studied Xxx-His class, in which a histidine at position 2 holds Cu(II) through three nitrogens and leaves a fourth site open.[4]

What is AHK-Cu?

GHK (glycyl-L-histidyl-L-lysine) was isolated from human plasma together with roughly equimolar copper, and early structure-function work reported that several tripeptides sharing the histidyl-lysyl linkage were nearly as active as GHK in hepatoma cell culture. AHK keeps the His-Lys pair and replaces glycine with alanine; the 1980 abstract does not say whether AHK itself was among the peptides tested.[19]

The earliest document found that names AHK-Cu specifically is a United States patent filed by Loren Pickart and assigned to ProCyte, granted in 1996 with priority back to 1985. It claims L-alanyl-L-histidyl-L-lysine:copper(II), and its L-valyl counterpart, as compounds. The text gives only a general preparation (a copper salt added to the peptide in water, then neutralised) and reports no data for the alanine complex.[14]

AHK-Cu is a small metal complex rather than a receptor ligand with a known target. It should not be confused with GHK-Cu, with the copper-free peptide AHK, or with a vitamin C conjugate of AHK that has been studied without copper.[13,17]

Not to be confused with

GHK-Cu (Gly-His-Lys copper complex)
The parent compound: glycine, not alanine, at the N-terminus. In cosmetic ingredient naming the pair is numbered, GHK-Cu as Copper Tripeptide-1 and this complex as Copper Tripeptide-3, which states the one-residue difference more precisely than either trivial name does. GHK-Cu has its own registry entries, solution and crystal structures and measured copper affinity; none of those measurements was made on AHK-Cu, so GHK-Cu data describe a related molecule, not this one.[20,25,21,12,3]
AHK (copper-free Ala-His-Lys)
The same tripeptide without bound copper, registered as CAS 126828-32-8 and FDA UNII 1AVY5QO8WR (C15H26N6O4, 354.41 g/mol). It is the ligand of AHK-Cu, not the complex, and research-grade material under this name is catalogued as a trifluoroacetate salt at a purity specification of at least 95 percent.[13,6,28]
Vitamin C-linker-conjugated AHK (Vit C-AHK)
Ala-His-Lys chemically joined to ascorbic acid through a linker and studied without copper. Findings for this conjugate are not findings for AHK-Cu.[17]
Ala-His-His (AHH) copper complexes
A different tripeptide that shares the Ala-His N-terminus but carries a second histidine, which lets it switch to a four-nitrogen copper site that AHK cannot form.[15,29]
Cu(II)-DAHK (albumin N-terminal motif)
Asp-Ala-His-Lys has histidine at position 3 and binds copper through four peptide nitrogens (an ATCUN site). AHK has histidine at position 2, which belongs to the three-nitrogen Xxx-His class.[4,25]
Arg-His-Lys, also abbreviated AHK in at least one paper
A 2021 study of synthetic dimeric peptides in human follicle dermal papilla cells expands AHK as Arg-His-Lys in its abstract, which is a different sequence from the Ala-His-Lys of this entry. The abbreviation is therefore not by itself a reliable statement of which tripeptide a paper used; the expanded name or a registry identifier is.[18]

AHK-Cu structure and sequence

The ligand is a linear tripeptide, H-Ala-His-Lys-OH, with three L stereocentres, a free N-terminal amine and a free C-terminal carboxylate (C15H26N6O4, 354.41 g/mol). Binding one Cu(II) ion with loss of two protons gives the neutral 1:1 complex C15H24CuN6O4, about 415.9 g/mol; the registered PubChem form carries an additional hydrochloride.[13,6,5]

Peptides with histidine at position 2 bind Cu(II) through three nitrogens in a plane: the N-terminal amine, the nitrogen of the first peptide bond (which copper deprotonates) and the imidazole of histidine. A fourth position is left to water or an external ligand. AHK-Cu is expected to follow this pattern, and the alanine methyl group sits next to the amine that binds copper, but its affinity, its pH profile and whether it forms 2:1 peptide-to-copper species have not been measured.[4,15,20]

No 3D view is shown. No structure of AHK-Cu has been deposited, and the only computed conformer in PubChem belongs to the copper-free peptide.[13,5]

Modifications

  • Ala1 alpha-amine, Ala1-His2 amide nitrogen, His2 imidazole nitrogen Expected equatorial Cu(II) site, by analogy with every studied Xxx-His peptide: the N-terminal amine, the deprotonated amide nitrogen of the first peptide bond and the histidine imidazole form two fused chelate rings, leaving a fourth equatorial position for water or another ligand. The PubChem name for the complex draws the copper on the alanine nitrogen, the histidine amide nitrogen and the imidazole N3. No spectroscopic or crystallographic study of AHK-Cu itself was found to confirm this.[4,15,5]
  • Lys3 side-chain amine In the parent complex Cu(II)-GHK the lysine side-chain amine is protonated and not bound to copper at physiological pH. The same is expected for AHK but has not been measured.[16,22]

Three stereocentres, all S: L-alanine, L-histidine and L-lysine, as recorded for the free peptide by PubChem and by the FDA substance registry (absolute stereochemistry). Copper coordination adds no new stereocentre. The geometry of the copper site has not been determined for this peptide; the description above is an inference from the GHK and Xxx-His literature.[13,6,4]

What studies on AHK-Cu show

Each card names the experimental system and what was measured. A result in one system is not evidence about another.

Organ culture and cell culture · Human scalp hair follicles cultured ex vivo (tissue taken from the body and kept alive in culture); cultured human dermal papilla cells, the specialised fibroblasts of the small cluster of connective tissue at the base of a hair follicle

Assay concentrations of 10^-12 to 10^-9 M increased follicle elongation and papilla cell proliferation. At 10^-9 M the Bcl-2/Bax ratio rose and cleaved caspase-3 and PARP fell; the fall in apoptotic cell counts was not statistically significant. A chemical supplier's product record for the complex, reading the same paper's full text, states the elongation effect as a rise between 0.001 and 1 nM and a fall between 10 and 100 nM, so the measured direction reverses within the range tested.[1]

Material
L-alanyl-L-histidyl-L-lysine-Cu2+; preparation and copper-to-peptide ratio not given in the abstract
Measured
Follicle shaft elongation; papilla cell proliferation; annexin V/propidium iodide staining; Bcl-2/Bax ratio; cleaved caspase-3 and PARP by western blot
Compared with
Not described in the abstract; no copper-free AHK, copper salt or GHK-Cu arm is mentioned
Limitation
A single laboratory's in vitro and ex vivo work. The paper was read here as its PubMed abstract, through a 2026 review that summarises it, and through a chemical supplier's product record that quotes figures from the full text; the full text itself was not read, so the higher-concentration reversal rests on the supplier's reading. The abstract does not describe how the complex was prepared or characterised, does not report a comparison with copper-free AHK, copper alone or GHK-Cu, and does not establish a molecular target. The apoptotic cell count change was not statistically significant.

Pyo HK et al., 2007, Arch Pharm Res

Solution spectroscopy and NMR · Aqueous solution across a pH range

With the Ala-His N-terminus the peptide formed the three-nitrogen Xxx-His type complex at pH about 4 to 6.5, switching to a four-nitrogen form above pH 6.5 because of the second histidine. Copper exchange between peptides was fast.[15]

Material
Ala-His-His and its C-terminal amide, with Cu(II)
Measured
Copper coordination mode and copper exchange rate
Compared with
Ala-Ala-His (four-nitrogen motif)
Limitation
The third residue is histidine, not lysine, so the four-nitrogen form is not available to AHK. The experiment shows that an Ala-His start supports the three-nitrogen site; it did not measure AHK.

Gonzalez P et al., 2017, Inorg Chem

Potentiometry, calorimetry, UV-visible, circular dichroism and EPR; serum stability; cell growth assay · Aqueous solution; human serum; cultured cells

The lysine side-chain amine was protonated at physiological pH and bound copper only at alkaline pH. The authors concluded that copper complexation driven by the first residue, and a free lysine side chain, mattered for growth-factor activity in their assay.[16]

Material
GHK and two analogues with histidine replaced by synthetic amino acids
Measured
Copper complex species and stability; lysine side-chain coordination; peptide survival in serum; cell growth
Compared with
GHK
Limitation
The analogues change position 2, not position 1, and AHK was not tested. Nothing in the study measures the effect of a glycine to alanine change; it is included only for the lysine side-chain and serum-stability observations on the GHK scaffold.

Conato C et al., 2001, Biochim Biophys Acta

Cell culture signalling and gene-expression assay · Mouse C2C12 myoblasts stimulated with BMP-2

The conjugate increased C2C12 proliferation, BMP-2-induced alkaline phosphatase and Smad1/5/8, ERK1/2 and p38 phosphorylation.[17]

Material
Vitamin C-linker-conjugated Ala-His-Lys, without copper
Measured
Proliferation; alkaline phosphatase induction; Smad1/5/8, ERK1/2 and p38 phosphorylation; osteoblast marker mRNAs
Compared with
BMP-2 without the conjugate
Limitation
A different molecule from AHK-Cu: the peptide is covalently joined to ascorbic acid and no copper was used, so the result cannot be transferred to the copper complex.

Jung JI et al., 2018, Differentiation

Cell culture proliferation and signalling assay · Cultured human follicle dermal papilla cells

The dimeric derivatives increased papilla cell proliferation more than the AHK comparator did, and increased ERK1/2 phosphorylation; one dimer, Arg-Trp-Lys, gave the strongest ERK1/2 signal and raised VEGF, FGF-2 and FGF-7 mRNA. The authors report no significant cytotoxicity.[18]

Material
Synthetic dimeric peptide derivatives; copper-free AHK as the comparator peptide. The abstract expands AHK as Arg-His-Lys rather than Ala-His-Lys
Measured
Cell proliferation; ERK1/2 phosphorylation; VEGF, FGF-2 and FGF-7 mRNA
Compared with
Copper-free AHK
Limitation
No copper was used, so this is not a study of AHK-Cu, and the AHK arm is a comparator rather than the subject. Which tripeptide that arm contained is uncertain, because the abstract expands AHK as Arg-His-Lys. Read as an abstract only. The one thing it does say about the ligand is that synthetic dimers outperformed it in this assay.

Jeong J et al., 2021, Bull Korean Chem Soc

How an Ala-His N-terminus is expected to hold copper(II)

Copper(II) is one of few metal ions that can strip the proton from a peptide-bond nitrogen and bind it. In an Xxx-His peptide this produces a five-membered ring through the N-terminal amine and amide nitrogen and a six-membered ring through the amide nitrogen and the histidine imidazole. Measured conditional affinities for this class at pH 7.4 fall roughly between 10^11 and 10^13 per molar, and for Cu(II)-GHK the isothermal titration calorimetry figure corresponds to a dissociation constant near 7 x 10^-14 M.[4,21]

In the four-nitrogen Xxx-Zzz-His class, the basicity of the N-terminal amine was reported as the main determinant of affinity across substitutions at position 1. No equivalent series was found for Xxx-His peptides, so the size of the shift caused by replacing glycine with alanine in AHK is unknown. The open fourth site is what lets Cu(II)-GHK form ternary complexes with histidine, glycine, cis-urocanic acid and histidines on serum albumin, and lets copper move quickly between GHK molecules. In the assays collected in the 2018 review, the Xxx-His copper complexes tested did not oxidise ascorbate efficiently, although they are more redox-active than four-nitrogen complexes; an Xxx-His motif attached to an antimicrobial peptide produced little reactive oxygen.[4,22,23,24,25,26,27]

All of these statements describe the class and the parent compound. None has been tested on AHK-Cu, and the one cell study of AHK-Cu did not identify which copper species or which cellular target its measurements depended on.[1]

An abstract illustration standing for the kind of process this entry describes. It depicts no molecule and carries no text.
An abstract illustration, chosen to suit the kind of process this page describes. It is decoration rather than evidence: nothing in it is specific to this compound, nothing in it was measured, and it depicts no molecule. Generated from this entry's topic list. Volta Peptides compound library. CC0 1.0

What is still unknown about AHK-Cu

The published record of AHK-Cu is very thin: one primary study, known here from its abstract, from a 2026 review that summarises it and from a chemical supplier's product record quoting its full text, plus a patent claim without data. No independent replication was found, and no human study of any design was found.[1,2,3,14]

The chemistry of the complex is unmeasured. There is no stability constant, no spectroscopic assignment and no crystal structure for Cu(II)-AHK, so its copper-to-peptide ratio in solution, its exchange behaviour and its redox properties are inferred from GHK and related peptides.[4]

Registry identity remains partial even with the sector name settled. The FDA substance registry and ChEBI list only the copper-free peptide; PubChem's copper record rests on a depositor-supplied CAS number that could not be checked against the CAS Registry, and its computed charge of -1 reflects how the structure was drawn rather than a measured species. The cosmetic-sector name Copper Tripeptide-3 is attached to this structure by suppliers' records and by PubChem's depositor synonyms, but a CosIng inventory search found no entry under that name, so no regulator's own inventory record for the complex was located.[6,5,3]

The abbreviation itself is unsafe to rely on. One published abstract uses AHK for Arg-His-Lys, so a paper citing AHK without expanding it cannot be assumed to concern Ala-His-Lys.[18]

Key papers on AHK-Cu

  1. The effect of tripeptide-copper complex on human hair growth in vitro.

    Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH (2007), Arch Pharm Res · Primary in vitro and ex vivo study

    The only primary study of AHK-Cu itself, in human follicle organ culture and dermal papilla cells.

  2. N-Terminal Cu-Binding Motifs (Xxx-Zzz-His, Xxx-His) and Their Derivatives: Chemistry, Biology and Medicinal Applications.

    Gonzalez P, Bossak K, Stefaniak E, Hureau C, Raibaut L, Bal W, Faller P (2018), Chemistry · Review

    The clearest account of how Xxx-His peptides such as AHK bind copper(II), with affinity ranges, exchange kinetics and redox behaviour.

  3. Metal-peptide compositions and methods for stimulating hair growth

    Pickart LR (inventor); ProCyte Corporation (assignee) (1996), US Patent 5,550,183 · Patent

    Where AHK-Cu first appears as a named compound, and a record of how it was framed as a GHK analogue.

  4. Structure of the Glycyl-L-histidyl-L-lysine--copper(II) complex in solution.

    Freedman JH, Pickart L, Weinstein B, Mims WB, Peisach J (1982), Biochemistry · Spectroscopic structure study

    The solution-structure study of the parent complex Cu(II)-GHK, which defines the three-nitrogen site AHK is expected to share.

  5. Cu(II) Binding to the Peptide Ala-His-His, a Chimera of the Canonical Cu(II)-Binding Motifs Xxx-His and Xxx-Zzz-His.

    Gonzalez P, Vileno B, Bossak K, El Khoury Y, Hellwig P, Bal W, Hureau C, Faller P (2017), Inorg Chem · Spectroscopic study

    Direct spectroscopy of copper bound to a peptide that starts with Ala-His, the same N-terminus as AHK.

References

  1. 1.Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. (2007). The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 30:834-839. doi:10.1007/BF02978833 · abstract only
  2. 2.Fan C, Chen Y, Huang Q, Ou WY, Zhang C, Sun Y, Wu T, Leung OY, Iu HC, Shi J. (2026). Overview of Short Peptides for Hair Loss. Biomedicines. 14:864. doi:10.3390/biomedicines14040864 · full text read
  3. 3.Cayman Chemical. (2026). Copper Tripeptide-3 (hydrochloride), Item No. 45777: product record for [L-alanyl-kN-L-histidyl-kN,kN3-L-lysinato(2-)]-copper, dihydrochloride. Cayman Chemical product records. source · full text read
  4. 4.Gonzalez P, Bossak K, Stefaniak E, Hureau C, Raibaut L, Bal W, Faller P. (2018). N-Terminal Cu-Binding Motifs (Xxx-Zzz-His, Xxx-His) and Their Derivatives: Chemistry, Biology and Medicinal Applications. Chemistry. 24:8029-8041. doi:10.1002/chem.201705398 · full text read
  5. 5.National Center for Biotechnology Information. PubChem Compound record for AHK-Cu, [L-alanyl-N-L-histidyl-N,N3-L-lysinato(2-)]copper monohydrochloride (CID 168431292). PubChem. source · database record
  6. 6.U.S. Food and Drug Administration Global Substance Registration System. ALANYLHISTIDYLLYSINE (UNII 1AVY5QO8WR). FDA GSRS. source · database record
  7. 7.World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026. World Anti-Doping Agency. source · full text read
  8. 8.U.S. Food and Drug Administration. (2026). Drugs@FDA: FDA-Approved Drugs. U.S. Food and Drug Administration. source · database record
  9. 9.European Medicines Agency. (2026). Medicines. European Medicines Agency. source · database record
  10. 10.Health Canada. (2026). Drug Product Database online query. Health Canada. source · database record
  11. 11.U.S. Food and Drug Administration. (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 of the bulk substances nominated under sections 503A or 503B), content current as of 04/22/2026. U.S. Food and Drug Administration. source · full text read
  12. 12.U.S. Food and Drug Administration Global Substance Registration System. PREZATIDE COPPER (UNII 6BJQ43T1I9). FDA GSRS. source · database record
  13. 13.National Center for Biotechnology Information. PubChem Compound record for L-alanyl-L-histidyl-L-lysine (CID 7408502). PubChem. source · database record
  14. 14.Pickart LR (inventor); ProCyte Corporation (assignee). (1996). Metal-peptide compositions and methods for stimulating hair growth. US Patent 5,550,183. source · full text read
  15. 15.Gonzalez P, Vileno B, Bossak K, El Khoury Y, Hellwig P, Bal W, Hureau C, Faller P. (2017). Cu(II) Binding to the Peptide Ala-His-His, a Chimera of the Canonical Cu(II)-Binding Motifs Xxx-His and Xxx-Zzz-His. Inorg Chem. 56:14870-14879. doi:10.1021/acs.inorgchem.7b01996 · abstract only
  16. 16.Conato C, Gavioli R, Guerrini R, Kozlowski H, Mlynarz P, Pasti C, Pulidori F, Remelli M. (2001). Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity. Biochim Biophys Acta. 1526:199-210. doi:10.1016/s0304-4165(01)00127-1 · abstract only
  17. 17.Jung JI, Park KY, Lee Y, Park M, Kim J. (2018). Vitamin C-linker-conjugated tripeptide AHK stimulates BMP-2-induced osteogenic differentiation of mouse myoblast C2C12 cells. Differentiation. 101:1-7. doi:10.1016/j.diff.2018.03.001 · abstract only
  18. 18.Jeong J, Park KY, Kim J. (2021). Synthesis and biological evaluation of dimeric peptide derivatives as proliferation-stimulating agents in human follicle dermal papilla cells. Bull Korean Chem Soc. 42:1435-1439. doi:10.1002/bkcs.12395 · abstract only
  19. 19.Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. (1980). Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 288:715-717. doi:10.1038/288715a0 · abstract only
  20. 20.Freedman JH, Pickart L, Weinstein B, Mims WB, Peisach J. (1982). Structure of the Glycyl-L-histidyl-L-lysine--copper(II) complex in solution. Biochemistry. 21:4540-4544. doi:10.1021/bi00262a004 · abstract only
  21. 21.Trapaidze A, Hureau C, Bal W, Winterhalter M, Faller P. (2012). Thermodynamic study of Cu2+ binding to the DAHK and GHK peptides by isothermal titration calorimetry (ITC) with the weaker competitor glycine. J Biol Inorg Chem. 17:37-47. doi:10.1007/s00775-011-0824-5 · abstract only
  22. 22.Lau SJ, Sarkar B. (1981). The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 199:649-656. doi:10.1042/bj1990649 · abstract only
  23. 23.Bossak-Ahmad K, Wiśniewska MD, Bal W, Drew SC, Frączyk T. (2020). Ternary Cu(II) Complex with GHK Peptide and Cis-Urocanic Acid as a Potential Physiologically Functional Copper Chelate. Int J Mol Sci. 21:6190. doi:10.3390/ijms21176190 · abstract only
  24. 24.Bossak-Ahmad K, Bal W, Frączyk T, Drew SC. (2021). Ternary Cu(2+) Complexes of Human Serum Albumin and Glycyl-l-histidyl-l-lysine. Inorg Chem. 60:16927-16931. doi:10.1021/acs.inorgchem.1c03084 · abstract only
  25. 25.Hureau C, Eury H, Guillot R, Bijani C, Sayen S, Solari PL, Guillon E, Faller P, Dorlet P. (2011). X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry. 17:10151-10160. doi:10.1002/chem.201100751 · abstract only
  26. 26.Bouraguba M, Glattard E, Naudé M, Pelletier R, Aisenbrey C, Bechinger B, Raibaut L, Lebrun V, Faller P. (2020). Copper-binding motifs Xxx-His or Xxx-Zzz-His (ATCUN) linked to an antimicrobial peptide: Cu-binding, antimicrobial activity and ROS production. J Inorg Biochem. 213:111255. doi:10.1016/j.jinorgbio.2020.111255 · abstract only
  27. 27.Frączyk T. (2021). Cu(II)-Binding N-Terminal Sequences of Human Proteins. Chem Biodivers. 18:e2100043. doi:10.1002/cbdv.202100043 · abstract only
  28. 28.Cayman Chemical. (2026). L-alanyl-L-histidyl-L-lysine (trifluoroacetate salt), Item No. 45938: product record for the copper-free tripeptide. Cayman Chemical product records. source · full text read
  29. 29.Gonzalez P, Bossak-Ahmad K, Vileno B, Wezynfeld NE, El Khoury Y, Hellwig P, Hureau C, Bal W, Faller P. (2019). Triggering Cu-coordination change in Cu(ii)-Ala-His-His by external ligands. Chem Commun (Camb). 55:8110-8113. doi:10.1039/c9cc03174j · abstract only

Scope. This entry describes chemistry, structure and published laboratory findings. It is not guidance on use of any kind.

Sources read: 25 distinct works. Researched 2026-11-03. Detailed review 2026-11-03. How this library is built.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.